Boston Scientific: Pipeline Will Aid Return To Growth By Year End
This article was originally published in The Gray Sheet
Executive Summary
Potential growth drivers identified by the firm during its April 19 first-quarter earnings call include the Ingenio family of pacemakers and BSX-manufactured Promus Element everolimus-eluting stent system.